Skip to content
Subscriber Only

Sanofi Won’t Chase Alzheimer’s Therapies, Viehbacher Says

Sanofi, unlike rivals such as Merck & Co., won’t push hard to find an Alzheimer’s treatment because the science isn’t advanced enough to justify the costs to develop a drug, Chief Executive Officer Chris Viehbacher said.

Sanofi, the French drugmaker that has gained 42 percent in the past year, “definitely” won’t commit major resources seeking to discover an Alzheimer’s therapy, Viehbacher said, in contrast to the strategy announced by rivals such as Merck, Eli Lilly & Co., Johnson & Johnson and Pfizer Inc.